First Trust Advisors LP Buys 133,841 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

First Trust Advisors LP boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 159.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 217,558 shares of the company's stock after buying an additional 133,841 shares during the quarter. First Trust Advisors LP owned approximately 0.18% of 10x Genomics worth $3,124,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Signaturefd LLC grew its holdings in 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after buying an additional 1,452 shares in the last quarter. Blue Trust Inc. lifted its stake in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. boosted its holdings in 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after acquiring an additional 4,324 shares during the period. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Stifel Nicolaus lowered their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Leerink Partnrs downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Leerink Partners cut 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Finally, UBS Group cut their target price on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $18.85.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares of the company's stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is owned by company insiders.

10x Genomics Trading Up 3.0 %

Shares of TXG traded up $0.26 during mid-day trading on Friday, hitting $8.89. The company's stock had a trading volume of 3,193,456 shares, compared to its average volume of 2,302,339. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $28.25. The firm has a market capitalization of $1.09 billion, a P/E ratio of -5.85 and a beta of 1.94. The firm has a 50-day simple moving average of $8.98 and a 200 day simple moving average of $12.62.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, sell-side analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.